<h1>FRAGMIN</h1><p> FRAGMINis contraindicated in patients with active major bleeding or with known hypersensitivity to the drug, heparin, or pork products, or with thrombocytopenia associated with a positive antiplatelet antibody test
Patients undergoing regional anesthesia should not receive FRAGMIN for unstable angina or non–Q-wave myocardial infarction, and patients with cancer undergoing regional anesthesia should not receive FRAGMIN for extended treatment of symptomatic VTE, due to an increased risk of bleeding associated with the dosage of FRAGMIN recommended for these indications
FRAGMIN Injection is not intended for intramuscular administration
FRAGMIN cannot be used interchangeably (unit for unit) with unfractionated heparin or other low–molecular-weight heparins
FRAGMIN, like other anticoagulants, should be used with extreme caution in patients who have an increased risk of hemorrhage; bleeding can occur at any site during therapy. An unexpected drop in hematocrit or blood pressure should lead to a search for a bleeding site</p>
Patients undergoing regional anesthesia should not receive FRAGMIN for unstable angina or non–Q-wave myocardial infarction, and patients with cancer undergoing regional anesthesia should not receive FRAGMIN for extended treatment of symptomatic VTE, due to an increased risk of bleeding associated with the dosage of FRAGMIN recommended for these indications
FRAGMIN Injection is not intended for intramuscular administration
FRAGMIN cannot be used interchangeably (unit for unit) with unfractionated heparin or other low–molecular-weight heparins
FRAGMIN, like other anticoagulants, should be used with extreme caution in patients who have an increased risk of hemorrhage; bleeding can occur at any site during therapy. An unexpected drop in hematocrit or blood pressure should lead to a search for a bleeding site</p>
